August Troendle Sells 6,830 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 6,830 shares of Medpace stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $598.49, for a total value of $4,087,686.70. Following the completion of the sale, the chief executive officer directly owned 855,485 shares in the company, valued at $511,999,217.65. This trade represents a 0.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Medpace Trading Down 1.2%

Shares of Medpace stock opened at $599.50 on Monday. The firm has a market cap of $16.89 billion, a PE ratio of 41.92, a PEG ratio of 2.67 and a beta of 1.42. The stock has a 50 day moving average of $560.60 and a 200 day moving average of $445.45. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of several research reports. BMO Capital Markets initiated coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Jefferies Financial Group increased their price target on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Finally, Mizuho upped their price objective on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $487.18.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. AQR Capital Management LLC raised its holdings in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Vulcan Value Partners LLC boosted its holdings in Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock valued at $99,159,000 after acquiring an additional 224,578 shares during the period. Norges Bank bought a new position in Medpace in the 2nd quarter valued at $66,597,000. Arrowstreet Capital Limited Partnership increased its stake in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Finally, Clarkston Capital Partners LLC bought a new stake in shares of Medpace during the second quarter worth $40,569,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.